Scientist Reveals the Hidden Programming of Death

Mitteldorf acknowledges that rapamycin is the best-studied pharmacological agent for lifespan extension in rodents, but human data are absent. He worries about immunosuppression and other risks of chronic mTOR inhibition, so he limits exposure to a brief annual course. He emphasizes that this is a personal experiment, not a prescription, and that the ideal schedule is entirely unknown.

Mitteldorf explains that insulin's role in aging is ancient and independent of its glucose-regulating function. All foods stimulate some insulin, but limiting eating windows reduces total daily insulin exposure more effectively than just restricting carbohydrates. He recommends experimenting to find a sustainable schedule, as no single protocol works for everyone.

The Biosphere 2 experiment accidentally provided human data: when participants were forced into caloric restriction due to poor food production, their biomarkers improved dramatically. This surprised Roy Walford and led him to dedicate his career to caloric restriction research. Mitteldorf sees this as evidence that human bodies respond to scarcity by becoming healthier.

Mitteldorf spent five years trying to model evolution that positively selects for shorter lifespan. The breakthrough came when he incorporated predator-prey dynamics: a species that reproduces too fast will destroy its food supply, causing its own extinction. This ecological feedback loop acts within a single generation, making community-level selection just as powerful as individual selection. Animals have therefore evolved built-in birth control and death control—aging—so that populations never outgrow their prey or plant resources. He cites the Rocky Mountain locust, which bloomed in massive swarms but then went extinct because it exhausted its food. The implication is that aging is not a flaw but an adaptive program that keeps ecosystems balanced.

In a small set of experiments spanning only about 30 rats, Catcher and two other labs extracted exosomes from young rats and injected them into old ones. The old rats not only looked and acted younger—improved cognition, stamina, skin—but one lived to twice the average rat lifespan, a record. Mitteldorf believes that exosomes are the body's master communication system for age status, and that rejuvenation can be achieved by resetting this signaling without needing to repair cellular damage or edit genes. However, research is starved of funding because there is no clear path to patents; investors fear that any breakthroughs would be copied by large players without profit. He estimates that with $50–100 million and a few years of intensive animal trials, exosome rejuvenation could be ready for human trials.

Mitteldorf explains that insulin's role in aging predates its metabolic function. In worms, insulin regulates lifespan directly, and in humans, chronically elevated insulin—from frequent eating or high carbohydrate loads—accelerates aging by keeping pro-aging pathways active. Lowering insulin, not to zero (which would cause diabetes), but to youthful levels, can modestly extend healthy years. He notes that time-restricted eating is often more effective than simple carbohydrate restriction for lowering fasting insulin because it reduces the number of times insulin is released.

Longo's finding was initially rejected by journals because it was deemed theoretically impossible. After years of resubmissions, the paper was published in Nature with robust evidence that the yeast cells were genetically identical and the suicide was biochemically similar to apoptosis. Mitteldorf uses this as a powerful illustration that group selection can and does operate, providing a conceptual bridge to understanding why aging—a group-level adaptation—could also evolve.

Mitteldorf contends that even if we could edit genes perfectly, it would be unnecessary because the body already knows how to be young—it just needs the correct signaling environment. Exosomes, which carry this signaling information, offer a simpler and potentially safer route to rejuvenation. He estimates we are decades away from safe whole-body gene editing, whereas exosome therapy might yield results much sooner if funded.